Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026

July 27, 2026
Insilico Medicine will present first in human Phase 1 data for ISM6331 at ESMO Congress 2026 in Madrid.
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026

Insilico Medicine announced in a press release that first in human Phase 1 trial data for ISM6331 has been accepted for a Rapid Oral presentation at the European Society for Medical Oncology Congress 2026.

The congress will take place from October 23 to 27, 2026, in Madrid. The presentation will cover results from a global Phase 1 multicenter study of ISM6331 in patients with mesothelioma and other advanced solid tumors.

ISM6331 is an AI designed oral inhibitor that targets TEAD transcription factors. The study evaluates safety, tolerability, and preliminary efficacy.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

07/27
deliverz.ai Brings Hospital Logistics Automation Platform to US
07/27
AssureCare and CURIS Partner on Rural Health Funding Support
07/27
Redox and Lapsi Health Connect Keikku Platform to EHR Systems
07/27
Natural Cycles Gets FDA Clearance for AI Fertility Algorithm
07/27
Care Career Acquires MAS Medical Staffing

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like